PwC has decided to scale back health insurance coverage for certain weight-loss medications for its US workforce. Starting July, employees will no longer receive reimbursement for GLP-1 drugs when used for weight management or related conditions. Coverage will continue only for cases where the medication is prescribed to treat type 2 diabetes.
As per the report by The Financial Times, the change surfaced during the annual benefits renewal process and has triggered concern among employees. Many had come to rely on these treatments as part of their broader health management. Some feel the move overlooks the challenges of maintaining a healthy lifestyle in demanding, desk-based roles that often involve long working hours.
The firm’s decision reflects a wider shift among large employers grappling with the escalating cost of these drugs. GLP-1 medications, widely used for both diabetes and weight loss, have surged in popularity in recent years. However, their high price has placed increasing pressure on corporate health plans.
PwC stated that the revision aligns with evolving industry practices and aims to balance employee healthcare needs with long-term cost sustainability. The company indicated it will continue reviewing trends and adjusting benefits accordingly.
Other organisations have taken similar steps. Some insurers and employers have already withdrawn coverage for weight-loss use of these medications unless tied to diabetes treatment.
The issue highlights a growing tension between expanding access to new healthcare treatments and managing the financial burden they create for employers.
